Portfolio company
Lir
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Lir develops AI-engineered viral vectors for gene therapy providers to improve treatment safety, precision targeting and immune system evasion.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Dyno Therapeutics
The company designs adeno-associated virus vectors for gene delivery using artificial intelligence for biopharmaceutical and pharmaceutical partners.
ZipBio
The company develops artificial intelligence to design gene therapies for pharmaceutical firms and biotechnology researchers.
Nanograb
This company develops an artificial intelligence platform to design targeted gene delivery vectors and nanoparticles for pharmaceutical organisations developing genetic medicines.
Gene Therapy Delivery Methods
This company develops viral and non-viral vector platforms to provide genetic material delivery solutions for biotechnology firms and healthcare providers.
Borea Therapeutics
The company develops bio-conjugated viral vectors for gene therapy to treat patients with genetic or chronic diseases.
Spot Biosystems
This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.
Stridebio
This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.
Salve Therapeutics
The company develops a bioengineering platform for designing and testing viral gene therapies to treat genetic disorders for biotechnology and pharmaceutical organisations.